Sequential Valproic Acid/All- trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Epigenetic alterations of chromatin due to aberrant histone deacetylase (HDAC) activity and transcriptional silencing of all-trans retinoic acid (ATRA) pathway are events linked to the pathogenesis of acute myeloid leukemia (AML) that can be targeted by specific treatments. A pilot study was carried out in eight refractory or high-risk AML patients not eligible for intensive therapy to assess the biological and therapeutic activities of the HDAC inhibitor valproic acid (VPA) used to remodel chromatin, followed by the addition of ATRA, to activate gene transcription and differentiation in leukemic cells. Hyperacetylation of histones H3 and H4 was detectable at therapeutic VPA serum levels (≥50 μg/mL) in blood mononuclear cells from seven of eight patients. This correlated with myelomonocytic differentiation of leukemic cells as revealed by morphologic, cytochemical, immunophenotypic, and gene expression analyses. Differentiation of the leukemic clone was proven by fluorescence in situ hybridization analysis showing the cytogenetic lesion +8 or 7q− in differentiating cells. Hematologic improvement, according to established criteria for myelodysplastic syndromes, was observed in two cases. Stable disease and disease progression were observed in five and one cases, respectively. In conclusion, VPA-ATRA treatment is well tolerated and induces phenotypic changes of AML blasts through chromatin remodeling. Further studies are needed to evaluate whether VPA-ATRA treatment by reprogramming differentiation of the leukemic clone might improve the response to chemotherapy in leukemia patients. (Cancer Res 2006; 66(17): 8903-11)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
A decade of molecular biology of retinoic acid receptors
Chambon, P. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.9.8801176 · Cited by 2,889 · cited 1×
“DNA was amplified by PCR using primers located on a promoter region encompassing the RARE of RARa2, the ATRA-inducible isoform of RARa related to myelomonocytic differentiation (17, 18, 37).”
MethodHeterochromatin and Epigenetic Control of Gene Expression
Grewal, S. I. S., & Moazed, D. (2003) · Science · doi:10.1126/science.1086887 · Cited by 1,065 · cited 1×
“In particular, deacetylation of the NH2terminal tails of histones H3 and H4 by HDACs inhibits transcription, whereas histones H3 and H4 acetylation by histone acetyltransferase (HAT) activities results in transcriptional activation by favoring access of DNA-binding proteins and of the transcriptional apparatus (2, 4,…”
BackgroundTranscription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735 · cited 1×
“Although we lack a direct proof for an ‘‘epigenetic priming’’ effect of VPA on gene transcription, in the two cases tested, VPA augmented the histone acetylation status on chromatin regions surrounding the RARE of RARa, the ATRA receptor gene involved in normal and pathologic myelopoiesis (16).”
BackgroundGlasow, A., Prodromou, N., Xu, K., von Lindern, M., & Zelent, A. (2005) · Blood · doi:10.1182/blood-2004-03-1074 · Cited by 68
Cited by
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Retinoids, Retinoic Acid Receptors, and Cancer
Tang, X.-H., & Gudas, L. J. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130303 · Cited by 596
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Self-citationSoriano, A. O., Yang, H., Faderl, S., Estrov, Z., Giles, F., Ravandi, F., Cortes, J., Wierda, W. G., Ouzounian, S., Quezada, A., et al. (2007) · Blood · doi:10.1182/blood-2007-03-078576 · Cited by 390
Differentiation therapy of leukemia: 3 decades of development.
Nowak, D., Stewart, D., & Koeffler, H. P. (2009) · Blood · doi:10.1182/blood-2009-01-198911 · Cited by 348
Metadata
- Authors
- Cimino, G., Lo-Coco, F., Fenu, S., Travaglini, L., Finolezzi, E., Mancini, M., Nanni, M., Careddu, A., Fazi, F., Padula, F., Fiorini, R., Aloe Spiriti, M. A., Petti, M. C., Venditti, A., Amadori, S., Mandelli, F., Pelicci, P. G., & Nervi, C.
- Venue
- Cancer Research
- Published
- 2006-09-01
- Volume
- 66
- Issue
- 17
- Pages
- 8903-8911
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2161186281
- Cited by
- 123
- References
- 6
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sequential Valproic Acid/All- trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-2726
- The paper
- Cimino, G., Lo-Coco, F., Fenu, S., Travaglini, L., Finolezzi, E., Mancini, M., Nanni, M., Careddu, A., Fazi, F., Padula, F., Fiorini, R., Aloe Spiriti, M. A., Petti, M. C., Venditti, A., Amadori, S., Mandelli, F., Pelicci, P. G., & Nervi, C. (2006). Sequential Valproic Acid/All- trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-2726
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.